ID   A-498
AC   CVCL_1056
SY   A498
DR   BTO; BTO:0003769
DR   CLO; CLO_0001596
DR   CLO; CLO_0009974
DR   EFO; EFO_0002105
DR   CLDB; cl163
DR   CLDB; cl164
DR   CLDB; cl5025
DR   CLDB; cl7160
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-7908
DR   ATCC; HTB-44
DR   BCRC; 60241
DR   BioSample; SAMN03471119
DR   BioSample; SAMN03472919
DR   BioSample; SAMN03473534
DR   BioSample; SAMN10987879
DR   cancercelllines; CVCL_1056
DR   CCRID; 1101HUM-PUMC000171
DR   Cell_Model_Passport; SIDM00124
DR   ChEMBL-Cells; CHEMBL3308425
DR   ChEMBL-Targets; CHEMBL614516
DR   CLS; 300113
DR   Cosmic; 687937
DR   Cosmic; 735612
DR   Cosmic; 845930
DR   Cosmic; 849378
DR   Cosmic; 874610
DR   Cosmic; 877453
DR   Cosmic; 905948
DR   Cosmic; 972874
DR   Cosmic; 972928
DR   Cosmic; 974301
DR   Cosmic; 982277
DR   Cosmic; 1092590
DR   Cosmic; 1152531
DR   Cosmic; 1175849
DR   Cosmic; 1305373
DR   Cosmic; 1312361
DR   Cosmic; 1995335
DR   Cosmic; 1998432
DR   Cosmic; 2520636
DR   Cosmic; 2653897
DR   Cosmic; 2663797
DR   Cosmic-CLP; 905948
DR   DepMap; ACH-000555
DR   DSMZ; ACC-55
DR   DSMZCellDive; ACC-55
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 905948
DR   GEO; GSM2132
DR   GEO; GSM50227
DR   GEO; GSM50291
DR   GEO; GSM743481
DR   GEO; GSM750836
DR   GEO; GSM799372
DR   GEO; GSM799435
DR   GEO; GSM846284
DR   GEO; GSM843438
DR   GEO; GSM886856
DR   GEO; GSM887921
DR   GEO; GSM1153445
DR   GEO; GSM1181297
DR   GEO; GSM1181323
DR   GEO; GSM1669587
DR   GEO; GSM2124636
DR   IARC_TP53; 21036
DR   ICLC; HTL04005
DR   IGRhCellID; A498
DR   IZSLER; BS TCL 111
DR   KCLB; 30044
DR   LiGeA; CCLE_161
DR   LINCS_LDP; LCL-1761
DR   Lonza; 1198
DR   NCI-DTP; A498
DR   PharmacoDB; A498_47_2019
DR   PRIDE; PXD003105
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1056
DR   PubChem_Cell_line; CVCL_1056
DR   SKY/M-FISH/CGH; 2783
DR   TOKU-E; 478
DR   Wikidata; Q54606041
RX   PubMed=327080;
RX   PubMed=375235;
RX   PubMed=450131;
RX   PubMed=571047;
RX   PubMed=833871;
RX   PubMed=2041050;
RX   PubMed=3335022;
RX   PubMed=4357758;
RX   PubMed=6244232;
RX   PubMed=6401685;
RX   PubMed=6825208;
RX   PubMed=6935474;
RX   PubMed=6954533;
RX   PubMed=7459858;
RX   PubMed=7915601;
RX   PubMed=8493574;
RX   PubMed=9488600;
RX   PubMed=10700174;
RX   PubMed=10723130;
RX   PubMed=10929426;
RX   PubMed=11146448;
RX   PubMed=15585611;
RX   PubMed=15604581;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=17409424;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22068913;
RX   PubMed=22282976;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=22949125;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=26759240;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=27993170;
RX   PubMed=28196595;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=37
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/a/cell-lines-detail-361.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 33 hours (PubMed=9488600); 58.4 hours (PubMed=22628656); ~62 hours (CLS=300113); ~60 hours (DSMZ=ACC-55); 66.8 hours (NCI-DTP=A498).
CC   HLA typing: A*02; B*08; C*07 (PubMed=15585611).
CC   HLA typing: A*02:01:01; B*08:01; C*07; DPB1*01:01:01; DQB1*02:01; DRB1*03:01:01 (PubMed=15748285).
CC   HLA typing: A*02:01,02:01; B*08:01,08:01; C*07:01,07:01; DQB1*02:02,06:07 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Val (c.3200A>T); Zygosity=Heterozygous (PubMed=26759240; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly144Serfs*14 (c.426_429delTGAC); Zygosity=Homozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Val142fs*30 (c.425_429delTTGAC); Zygosity=Unspecified (PubMed=8493574).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.37%; Native American=0%; East Asian, North=2.1%; East Asian, South=0%; South Asian=0%; European, North=63.47%; European, South=34.06% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7908; true.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; KCLB; PubMed=19372543; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 17
ST   D19S433: 12
ST   D21S11: 28,32
ST   D2S1338: 26
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 10,11 (ATCC; CCRID; Cosmic-CLP; DSMZ; KCLB; PubMed=19372543; PubMed=25877200)
ST   D7S820: 11,12 (CLS)
ST   D8S1179: 13,15
ST   FGA: 18,20
ST   Penta D: 9,14
ST   Penta E: 10,14
ST   TH01: 6,9.3
ST   TPOX: 8 (PubMed=25877200)
ST   TPOX: 8,11 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; KCLB; PubMed=19372543)
ST   vWA: 16,18 (DSMZ)
ST   vWA: 18 (ATCC; CCRID; CLS; Cosmic-CLP; KCLB; PubMed=19372543; PubMed=25877200)
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 44
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
//
RX   PubMed=450131; DOI=10.1038/279797a0;
RA   Day R.S. III, Ziolkowski C.H.J.;
RT   "Human brain tumour cell strains with deficient host-cell reactivation
RT   of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.";
RL   Nature 279:797-799(1979).
//
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=4357758; DOI=10.1093/jnci/51.5.1417;
RA   Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H.,
RA   Dosik H., Parks W.P.;
RT   "In vitro cultivation of human tumors: establishment of cell lines
RT   derived from a series of solid tumors.";
RL   J. Natl. Cancer Inst. 51:1417-1423(1973).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=6401685; DOI=10.1007/BF02617989;
RA   Halton D.M., Peterson W.D. Jr., Hukku B.;
RT   "Cell culture quality control by rapid isoenzymatic
RT   characterization.";
RL   In Vitro 19:16-24(1983).
//
RX   PubMed=6825208; DOI=10.1093/carcin/4.2.199;
RA   Yarosh D.B., Foote R.S., Mitra S., Day R.S. III;
RT   "Repair of O6-methylguanine in DNA by demethylation is lacking in Mer-
RT   human tumor cell strains.";
RL   Carcinogenesis 4:199-205(1983).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7915601; DOI=10.1038/ng0594-85;
RA   Gnarra J.R., Tory K., Weng Y., Schmidt L.S., Wei M.H., Li H., Latif F.,
RA   Liu S., Chen F., Duh F.-M., Lubensky I.A., Duan D.R., Florence C.,
RA   Pozzatti R., Walther M.M., Bander N.H., Grossman H.B., Brauch H.,
RA   Pomer S., Brooks J.D., Isaacs W.B., Lerman M.I., Zbar B.,
RA   Linehan W.M.;
RT   "Mutations of the VHL tumour suppressor gene in renal carcinoma.";
RL   Nat. Genet. 7:85-90(1994).
//
RX   PubMed=8493574; DOI=10.1126/science.8493574;
RA   Latif F., Tory K., Gnarra J.R., Yao M., Duh F.-M., Orcutt M.L.,
RA   Stackhouse T., Kuzmin I.A., Modi W., Geil L., Schmidt L.S., Zhou F.-W.,
RA   Li H., Wei M.H., Chen F., Glenn G., Choyke P., Walther M.M., Weng Y.-K.,
RA   Duan D.-S.R., Dean M., Glavac D., Richards F.M., Crossey P.A.,
RA   Ferguson-Smith M.A., Le Paslier D., Chumakov I., Cohen D.,
RA   Chinault A.C., Maher E.R., Linehan W.M., Zbar B., Lerman M.I.;
RT   "Identification of the von Hippel-Lindau disease tumor suppressor
RT   gene.";
RL   Science 260:1317-1320(1993).
//
RX   PubMed=9488600; DOI=10.1007/s002800050744;
RA   Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G.,
RA   Schellens J.H.M.;
RT   "Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a
RT   panel of eight solid-tumor cell lines in vitro.";
RL   Cancer Chemother. Pharmacol. 41:307-316(1998).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10723130; DOI=10.1038/sj.onc.1203449;
RA   Alimov A., Kost-Alimova M., Liu J., Li C.-D., Bergerheim U.S.R.,
RA   Imreh S., Klein G., Zabarovsky E.R.;
RT   "Combined LOH/CGH analysis proves the existence of interstitial 3p
RT   deletions in renal cell carcinoma.";
RL   Oncogene 19:1392-1399(2000).
//
RX   PubMed=10929426; DOI=10.1007/s002400000103;
RA   Shintaku I., Kawagoe N., Yutani S., Hoshi S., Orikasa S.,
RA   Yoshizumi O., Itoh K.;
RT   "Expression of the SART1 tumor rejection antigen in renal cell
RT   carcinoma.";
RL   Urol. Res. 28:178-184(2000).
//
RX   PubMed=11146448; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S;
RA   Kondo K.-i., Yao M., Kobayashi K., Ota S., Yoshida M., Kaneko S.,
RA   Baba M., Sakai N., Kishida T., Kawakami S., Uemura H., Nagashima Y.,
RA   Nakatani Y., Hosaka M.;
RT   "PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and
RT   renal carcinoma cell lines.";
RL   Int. J. Cancer 91:219-224(2001).
//
RX   PubMed=15585611; DOI=10.1158/1078-0432.CCR-04-0072;
RA   Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W.,
RA   Otterud B.E., Leppert M.F., Storb R., Sandmaier B.M.;
RT   "Allogeneic hematopoietic cell transplantation for metastatic renal
RT   cell carcinoma after nonmyeloablative conditioning: toxicity,
RT   clinical response, and immunological response to minor
RT   histocompatibility antigens.";
RL   Clin. Cancer Res. 10:7799-7811(2004).
//
RX   PubMed=15604581; DOI=10.1159/000081597;
RA   Ikemoto S., Sugimura K., Yoshida N., Kuratsukuri K., Wada S.,
RA   Nakatani T.;
RT   "Comparative antitumor activity of 5-fluorouracil and
RT   5'-deoxy-5-fluorouridine in combination with interferon-alpha in
RT   renal cell carcinoma cell lines.";
RL   Urol. Int. 73:348-353(2004).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17409424; DOI=10.1158/0008-5472.CAN-06-4571;
RA   Furge K.A., Chen J.-D., Koeman J., Swiatek P.J., Dykema K., Lucin K.,
RA   Kahnoski R., Yang X.-M.J., Teh B.T.;
RT   "Detection of DNA copy number changes and oncogenic signaling
RT   abnormalities from gene expression data reveals MYC activation in
RT   high-grade papillary renal cell carcinoma.";
RL   Cancer Res. 67:3171-3176(2007).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=22949125; DOI=10.1002/ijc.27822;
RA   Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.;
RT   "Loss of PBRM1 expression is associated with renal cell carcinoma
RT   progression.";
RL   Int. J. Cancer 132:E11-E17(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201;
RA   Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y.,
RA   Hampton G.M., Lackner M.R.;
RT   "Activating mutations in PIK3CB confer resistance to PI3K inhibition
RT   and define a novel oncogenic role for p110beta.";
RL   Cancer Res. 76:1193-1203(2016).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=27993170; DOI=10.1186/s12943-016-0565-8;
RA   Brodaczewska K.K., Szczylik C., Fiedorowicz M., Porta C.,
RA   Czarnecka A.M.;
RT   "Choosing the right cell line for renal cell cancer research.";
RL   Mol. Cancer 15:83.1-83.15(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//